Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Operating Leases (2022 - 2026)

Envoy Medical's Operating Leases history spans 5 years, with the latest figure at $711000.0 for Q1 2026.

  • On a quarterly basis, Operating Leases fell 8.61% to $711000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $711000.0, a 8.61% decrease, with the full-year FY2025 number at $745000.0, down 7.11% from a year prior.
  • Operating Leases hit $711000.0 in Q1 2026 for Envoy Medical, down from $745000.0 in the prior quarter.
  • Over the last five years, Operating Leases for COCH hit a ceiling of $1.1 million in Q2 2024 and a floor of $378000.0 in Q1 2024.
  • Historically, Operating Leases has averaged $730833.3 across 5 years, with a median of $728000.0 in 2025.
  • The widest YoY moves for Operating Leases: up 105.82% in 2025, down 37.29% in 2025.
  • Tracing COCH's Operating Leases over 5 years: stood at $565000.0 in 2022, then fell by 28.5% to $404000.0 in 2023, then skyrocketed by 98.51% to $802000.0 in 2024, then dropped by 7.11% to $745000.0 in 2025, then fell by 4.56% to $711000.0 in 2026.
  • Business Quant data shows Operating Leases for COCH at $711000.0 in Q1 2026, $745000.0 in Q4 2025, and $946000.0 in Q3 2025.